 Katja Aviszus
Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| B-Lymphocyte Subsets | 5 | 2020 | 86 | 1.150 |
Why?
| | Clonal Anergy | 5 | 2012 | 56 | 0.790 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2012 | 17 | 0.500 |
Why?
| | B-Lymphocytes | 10 | 2015 | 830 | 0.470 |
Why?
| | Antibody Formation | 2 | 2012 | 303 | 0.460 |
Why?
| | Immunologic Memory | 2 | 2007 | 311 | 0.350 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2007 | 38 | 0.350 |
Why?
| | Somatic Hypermutation, Immunoglobulin | 5 | 2013 | 18 | 0.330 |
Why?
| | Self Tolerance | 3 | 2012 | 31 | 0.320 |
Why?
| | Immunoglobulin Variable Region | 7 | 2011 | 83 | 0.310 |
Why?
| | Mice, Inbred A | 5 | 2012 | 57 | 0.270 |
Why?
| | Immunoglobulin G | 5 | 2017 | 793 | 0.270 |
Why?
| | Spleen | 3 | 2015 | 558 | 0.260 |
Why?
| | Cell Differentiation | 3 | 2007 | 1831 | 0.260 |
Why?
| | p-Azobenzenearsonate | 3 | 2012 | 5 | 0.230 |
Why?
| | Autoimmunity | 4 | 2013 | 775 | 0.230 |
Why?
| | Autoantigens | 3 | 2014 | 411 | 0.220 |
Why?
| | PPAR gamma | 1 | 2022 | 180 | 0.220 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 77 | 0.210 |
Why?
| | Adoptive Transfer | 4 | 2017 | 236 | 0.210 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2020 | 62 | 0.210 |
Why?
| | Genes, Immunoglobulin | 4 | 2010 | 36 | 0.200 |
Why?
| | Alveolitis, Extrinsic Allergic | 1 | 2020 | 89 | 0.200 |
Why?
| | Mice, Transgenic | 7 | 2012 | 2162 | 0.200 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2021 | 627 | 0.200 |
Why?
| | T-Lymphocyte Subsets | 2 | 2015 | 451 | 0.180 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2020 | 655 | 0.170 |
Why?
| | Mice | 17 | 2017 | 15587 | 0.170 |
Why?
| | Berylliosis | 1 | 2020 | 256 | 0.170 |
Why?
| | Antibodies, Antinuclear | 3 | 2014 | 70 | 0.170 |
Why?
| | Antigen-Antibody Complex | 1 | 2017 | 95 | 0.170 |
Why?
| | Receptors, Antigen, B-Cell | 3 | 2014 | 110 | 0.160 |
Why?
| | Mice, Inbred C57BL | 6 | 2015 | 5248 | 0.160 |
Why?
| | Lupus Erythematosus, Systemic | 2 | 2010 | 252 | 0.150 |
Why?
| | Haptens | 2 | 2007 | 24 | 0.150 |
Why?
| | Autoantibodies | 3 | 2015 | 1217 | 0.140 |
Why?
| | Antiviral Agents | 1 | 2021 | 637 | 0.140 |
Why?
| | Interleukin-4 | 1 | 2015 | 231 | 0.140 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 185 | 0.140 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2017 | 1073 | 0.140 |
Why?
| | Mice, Knockout | 4 | 2015 | 2893 | 0.130 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 1218 | 0.130 |
Why?
| | Mutation | 2 | 2021 | 3435 | 0.130 |
Why?
| | Immunoglobulin M | 1 | 2014 | 239 | 0.120 |
Why?
| | Mice, 129 Strain | 1 | 2012 | 84 | 0.120 |
Why?
| | Hybridomas | 3 | 2007 | 251 | 0.120 |
Why?
| | Hemocyanins | 3 | 2007 | 76 | 0.120 |
Why?
| | Germ-Line Mutation | 2 | 2005 | 132 | 0.120 |
Why?
| | Animals | 17 | 2017 | 35321 | 0.120 |
Why?
| | Immunoglobulin kappa-Chains | 4 | 2011 | 24 | 0.110 |
Why?
| | Cells, Cultured | 3 | 2015 | 4419 | 0.100 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2011 | 185 | 0.100 |
Why?
| | Immune Tolerance | 2 | 2017 | 367 | 0.090 |
Why?
| | Antibody-Producing Cells | 1 | 2007 | 29 | 0.090 |
Why?
| | Antibodies, Monoclonal | 3 | 2017 | 1297 | 0.090 |
Why?
| | Lymphocyte Activation | 2 | 2004 | 1167 | 0.090 |
Why?
| | Antibody Affinity | 1 | 2007 | 56 | 0.090 |
Why?
| | Immunoglobulin Heavy Chains | 2 | 2005 | 71 | 0.090 |
Why?
| | CD40 Ligand | 1 | 2007 | 47 | 0.090 |
Why?
| | Immunization, Secondary | 1 | 2007 | 76 | 0.090 |
Why?
| | Macrophages | 2 | 2022 | 1343 | 0.090 |
Why?
| | Antibody Specificity | 1 | 2007 | 198 | 0.090 |
Why?
| | Peptide Fragments | 1 | 2011 | 740 | 0.080 |
Why?
| | Immunoglobulin mu-Chains | 2 | 2003 | 7 | 0.080 |
Why?
| | Antibody Diversity | 1 | 2005 | 18 | 0.080 |
Why?
| | Transgenes | 2 | 2003 | 191 | 0.070 |
Why?
| | Protein Binding | 2 | 2021 | 2114 | 0.070 |
Why?
| | Gene Expression Regulation | 3 | 2022 | 2629 | 0.070 |
Why?
| | Interleukin-6 | 1 | 2007 | 705 | 0.070 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2022 | 60 | 0.060 |
Why?
| | Antigen-Antibody Reactions | 1 | 2021 | 54 | 0.060 |
Why?
| | Surface Plasmon Resonance | 1 | 2021 | 80 | 0.060 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 94 | 0.050 |
Why?
| | CD11c Antigen | 1 | 2020 | 39 | 0.050 |
Why?
| | Receptors, Virus | 1 | 2021 | 84 | 0.050 |
Why?
| | Receptors, Fc | 1 | 2020 | 43 | 0.050 |
Why?
| | Immunoglobulins | 1 | 2001 | 152 | 0.050 |
Why?
| | T-Box Domain Proteins | 1 | 2020 | 82 | 0.050 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 144 | 0.050 |
Why?
| | Antibodies, Neutralizing | 1 | 2021 | 170 | 0.050 |
Why?
| | Bone Marrow Cells | 1 | 2001 | 330 | 0.050 |
Why?
| | Receptors, Immunologic | 1 | 2020 | 212 | 0.050 |
Why?
| | Receptors, Complement 3d | 1 | 2020 | 166 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 1 | 2022 | 502 | 0.050 |
Why?
| | Oligonucleotides | 1 | 1999 | 151 | 0.050 |
Why?
| | Receptors, Cell Surface | 1 | 2020 | 402 | 0.040 |
Why?
| | Gene Expression | 3 | 2014 | 1586 | 0.040 |
Why?
| | Evolution, Molecular | 1 | 2002 | 455 | 0.040 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 316 | 0.040 |
Why?
| | Kinetics | 1 | 2021 | 1797 | 0.040 |
Why?
| | Binding Sites | 1 | 2021 | 1322 | 0.040 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2017 | 56 | 0.040 |
Why?
| | Base Sequence | 4 | 2003 | 2322 | 0.040 |
Why?
| | Flow Cytometry | 2 | 2014 | 1184 | 0.040 |
Why?
| | B-Cell Activating Factor | 1 | 2015 | 21 | 0.040 |
Why?
| | Germinal Center | 1 | 2015 | 54 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2017 | 308 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 1 | 2005 | 2418 | 0.040 |
Why?
| | Coculture Techniques | 1 | 2015 | 212 | 0.040 |
Why?
| | Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2014 | 13 | 0.030 |
Why?
| | Inflammation | 2 | 2022 | 2439 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2020 | 1092 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 2005 | 3120 | 0.030 |
Why?
| | Endocytosis | 1 | 2014 | 151 | 0.030 |
Why?
| | Antibodies | 1 | 2015 | 433 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2014 | 461 | 0.030 |
Why?
| | Humans | 7 | 2022 | 113117 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2020 | 3363 | 0.030 |
Why?
| | Radiation Chimera | 1 | 2011 | 39 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 1124 | 0.030 |
Why?
| | Complementarity Determining Regions | 1 | 2010 | 51 | 0.030 |
Why?
| | Codon | 2 | 2002 | 95 | 0.030 |
Why?
| | Blotting, Western | 1 | 2014 | 1316 | 0.030 |
Why?
| | Cell Membrane | 1 | 2014 | 771 | 0.020 |
Why?
| | Recombination, Genetic | 1 | 2010 | 178 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 309 | 0.020 |
Why?
| | Arginine | 1 | 2010 | 252 | 0.020 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2011 | 382 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2011 | 323 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2020 | 6786 | 0.020 |
Why?
| | snRNP Core Proteins | 1 | 2007 | 6 | 0.020 |
Why?
| | Mice, Inbred MRL lpr | 1 | 2007 | 47 | 0.020 |
Why?
| | Ribonucleoproteins, Small Nuclear | 1 | 2007 | 25 | 0.020 |
Why?
| | Calcium | 1 | 2014 | 1215 | 0.020 |
Why?
| | Receptors, IgE | 1 | 2006 | 43 | 0.020 |
Why?
| | Receptors, Complement | 1 | 2006 | 128 | 0.020 |
Why?
| | Mice, Inbred NZB | 1 | 2005 | 21 | 0.020 |
Why?
| | Young Adult | 1 | 2020 | 10943 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2013 | 1845 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2006 | 507 | 0.020 |
Why?
| | Arsanilic Acid | 1 | 2003 | 2 | 0.020 |
Why?
| | Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2003 | 15 | 0.020 |
Why?
| | Immunoglobulin Class Switching | 1 | 2003 | 18 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2003 | 170 | 0.020 |
Why?
| | Sequence Alignment | 1 | 2003 | 371 | 0.020 |
Why?
| | Epitopes | 1 | 2004 | 430 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2005 | 1328 | 0.010 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2003 | 330 | 0.010 |
Why?
| | Aged | 1 | 2020 | 20070 | 0.010 |
Why?
| | Chromatin | 1 | 2005 | 435 | 0.010 |
Why?
| | Immunoglobulin delta-Chains | 1 | 2001 | 1 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2007 | 761 | 0.010 |
Why?
| | Cell Lineage | 1 | 2003 | 365 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 2002 | 420 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2005 | 2229 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2004 | 611 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2010 | 3908 | 0.010 |
Why?
| | DNA, Single-Stranded | 1 | 2001 | 110 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2000 | 298 | 0.010 |
Why?
| | Base Composition | 1 | 1999 | 78 | 0.010 |
Why?
| | Immunoglobulin Light Chains | 1 | 1999 | 35 | 0.010 |
Why?
| | Middle Aged | 1 | 2020 | 28724 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2006 | 1644 | 0.010 |
Why?
| | Point Mutation | 1 | 2000 | 258 | 0.010 |
Why?
| | DNA Primers | 1 | 2000 | 598 | 0.010 |
Why?
| | RNA Splicing | 1 | 2000 | 243 | 0.010 |
Why?
| | Adult | 1 | 2020 | 31892 | 0.010 |
Why?
| | DNA Repair | 1 | 2000 | 187 | 0.010 |
Why?
| | Male | 2 | 2020 | 60883 | 0.010 |
Why?
| | Female | 2 | 2020 | 62850 | 0.010 |
Why?
| | Alleles | 1 | 2001 | 905 | 0.010 |
Why?
| | Kidney | 1 | 2004 | 1206 | 0.010 |
Why?
| | Nucleic Acid Conformation | 1 | 1999 | 703 | 0.010 |
Why?
| | RNA | 1 | 2000 | 775 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2000 | 1474 | 0.010 |
Why?
| | RNA, Messenger | 1 | 1999 | 2853 | 0.010 |
Why?
| | Biomarkers | 1 | 2001 | 3479 | 0.010 |
Why?
|
|
Aviszus's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|